Table 2 Escape latency data of compounds 8, 9, 10, 15, 16, 17, 18, 19 and 23.

From: Investigation, scaffold hopping of novel donepezil-based compounds as anti-Alzhiemer’s agents: synthesis, in-silico and pharmacological evaluations

Compound

μM of AChE/min/mg protein

LPO assay, MDA levels (nM/mg of tissue)

Nitrite assay, nitrite conc. (μM/mg) protein

GSH assay, μmol of GSH/mg Protein

SOD assay, SOD units/mg protein

Catalase assay, Catalase activity min−1

Control

0.03 ± 0.01

16.78 ± 0.04

17.88 ± 0.06

0.28 ± 0.001

4.6 ± 0.03

11.61 ± 0.07

Scopolamine

0.05 ± 0.056

25.09 ± 0.03

31.21 ± 0.06

0.08 ± 0.002

0.78 ± 0.01

2.25 ± 0.031

Donepezil

0.02 ± 0.01

16.76 ± 0.04

16.63 ± 0.06

0.18 ± 0.001

3.0 ± 0.03

10.3 ± 0.09

8

0.01 ± 0.01

9.71 ± 0.03

11.92 ± 0.05

0.11 ± 0.001

4.07 ± 0.03

5.23 ± 0.02

9

0.01 ± 0.01

8.48 ± 0.02

10.42 ± 0.04

0.11 ± 0.002

4.09 ± 0.02

6.23 ± 0.02

10

0.01 ± 0.01

8.52 ± 0.05

12.82 ± 0.04

0.10 ± 0.005

3.07 ± 0.04

4.3 ± 0.01

15

0.02 ± 0.02

8.54 ± 0.02

14.66 ± 0.04

0.09 ± 0.003

3.14 ± 0.03

5.35 ± 0.03

16

0.01 ± 0.01

8.52 ± 0.05

11.74 ± 0.03

0.11 ± 0.002

3.07 ± 0.02

4.66 ± 0.04

17

0.02 ± 0.01

8.73 ± 0.05

12.57 ± 0.05

0.11 ± 0.006

3.09 ± 0.02

4.76 ± 0.02

18

0.01 ± 0.01

8.52 ± 0.02

10.51 ± 0.03

0.11 ± 0.001

4.08 ± 0.02

5.53 ± 0.01

19

0.01 ± 0.02

9.25 ± 0.02

11.31 ± 0.03

0.09 ± 0.005

3.09 ± 0.03

5.17 ± 0.05

23

0.01 ± 0.04

9.77 ± 0.04

15.2 ± 0.03

0.10 ± 0.007

3.07 ± 0.02

5.13 ± 0.03

  1. The values are shown as mean ± SD, p < 0.05 as compared to scopolamine. One-way ANOVA followed by Tukey’s test was employed to find out the intergroup variation and values are considered statistically significant (p < 0.0001).
  2. AChE acetylcholinesterase, GSH reduced glutathione, LPO lipid peroxidation; MDA malondialdehyde, SD standard deviation, SOD superoxide dismutase.